Avecia Biotechnology, Inc. and Pfizer Inc. Enter into Manufacturing Agreement

MILFORD, Mass.--(BUSINESS WIRE)-- Avecia Biotechnology, Inc., a leading provider of drug development and manufacturing services for oligonucleotide therapeutics, has reached agreement with Pfizer Inc. regarding the commercial supply of a key component of Macugen® (pegaptanib sodium injection), marketed in the E.U. by Pfizer for the treatment of wet Age-Related Macular Degeneration.

The agreement includes technology transfer, process validation and commercial supply of a key component of Macugen®.

“The agreement with Pfizer to manufacture a key component of this commercial oligonucleotide-based therapeutic is testament to our experience, reliability and quality standards with regard to technology transfer, process validation and the manufacture of oligonucleotide drug substances,” says Detlef Rethage, President of Avecia Biotechnology, Inc.

About Avecia

Avecia Biotechnology, Inc. is a drug development and manufacturing service company located in Milford, Mass. The company is a recognized leader in process development, manufacturing and related services for DNA and RNA-based therapeutics and offers in Milford the world's largest established manufacturing capacity to work successfully with major pharmaceutical and innovative biotechnology companies. All services are offered - from pre-clinical testing to post-commercial launch of innovative oligonucleotide-based therapeutics. For additional information, visit http://www.aveciabiotech.com.


Avecia Biotechnology, Inc.
Paula Lorence, +1-508-532-2500
VP, Business Development
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Optical  Pharmaceutical  Research  Science



Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.